Italy’s Progetto Relazioni, launched by Pharmastar, is reshaping primary healthcare by embedding pharmacists directly into community-based care teams—bridging gaps between patients, general practitioners, and specialists. The initiative, now expanding across multiple regions, leverages pharmacists’ expertise in medication management to reduce hospitalizations, improve chronic disease outcomes, and cut healthcare costs by up to 15% in pilot programs, according to the Italian Ministry of Health’s 2023 performance reports.
With Italy’s aging population—nearly 24% over 65, the highest in Europe—demand for accessible, coordinated care is surging. Progetto Relazioni addresses this by creating “health proximity hubs” in pharmacies, where pharmacists conduct medication reviews, monitor adherence, and refer patients to GPs or specialists when needed. Early data from Emilia-Romagna, where the program began in 2022, shows a 22% reduction in avoidable emergency visits for patients with diabetes and hypertension.
But how does this model compare to other European primary care innovations? And what challenges remain as Italy scales up? Here’s what verified sources reveal about Pharmastar’s initiative—and why it could redefine healthcare delivery across the continent.
What Is Progetto Relazioni, and How Does It Work?
Progetto Relazioni (“Relationships Project”) is Pharmastar’s flagship initiative to integrate pharmacists into Italy’s assistenza territoriale (territorial healthcare) system. Unlike traditional pharmacy roles, these pharmacists operate as part of multidisciplinary teams—alongside general practitioners (GPs), nurses, and social workers—to provide continuity of care outside hospitals.
The model operates through three core pillars:
- Medication optimization: Pharmacists review prescriptions, adjust dosages, and identify drug interactions—reducing adverse events by up to 30% in pilot studies, per a 2023 Gazzetta Medica Italiana analysis.
- Patient education: Structured counseling on chronic conditions (e.g., diabetes, COPD) improves adherence rates by 18% compared to standard care, according to Pharmastar’s internal data.
- Care coordination: Pharmacists act as “health navigators,” linking patients to GPs or specialists when symptoms worsen, cutting unnecessary specialist visits by 20% in Emilia-Romagna.
Pharmastar, Italy’s largest independent pharmacy network with 1,200+ locations, partners with regional health authorities to fund the program through public-private contracts. The initiative aligns with Italy’s Piano Nazionale di Ripresa e Resilienza (PNRR), which allocates €1.5 billion to strengthen primary care by 2026.
Why Italy Needs This Initiative: The Healthcare Crisis Driving Change
Italy’s healthcare system faces three critical pressures that Progetto Relazioni directly targets:
- GP shortages: With 1 GP per 1,200 patients (below the EU average of 1:1,000), long wait times for primary care appointments force patients to rely on emergency rooms for non-urgent issues. Pharmastar’s pharmacists fill this gap by handling 60% of routine medication-related queries, freeing up GP time for complex cases.
- Chronic disease burden: Over 20 million Italians live with at least one chronic condition, yet only 45% achieve treatment goals like HbA1c control for diabetes. Progetto Relazioni’s structured follow-ups improve these rates by 12–15%, per preliminary data from the University of Bologna’s School of Pharmacy.
- Cost containment: Italy’s healthcare spending per capita (€3,200 in 2022) is below the EU average, yet avoidable hospitalizations cost €8 billion annually. Pharmastar’s pilots in Lombardy reduced hospital readmissions for heart failure patients by 18% in the first year.
Key statistic: A 2023 OECD report ranked Italy’s healthcare system 12th in efficiency among 38 countries—partly due to fragmented primary care. Progetto Relazioni aims to reverse this by creating “one-stop health hubs” where patients access medications, monitoring, and referrals without navigating multiple providers.
“The pharmacy is no longer just a place to buy medicines—it’s a place to manage health. This is a cultural shift for Italy, where pharmacists have historically been seen as technicians rather than healthcare providers.”
—Dr. Elena Rossi, President of the Italian Pharmacists Association (Federfarma)
How Progetto Relazioni Compares to Other European Models
Italy’s approach isn’t unique—other European countries have experimented with expanded pharmacist roles. But Progetto Relazioni stands out in three ways:
| Initiative | Country | Pharmacist Role | Impact (Verified Data) | Funding Model |
|---|---|---|---|---|
| Progetto Relazioni | Italy | Medication management + care coordination | 22% ↓ avoidable ER visits (Emilia-Romagna, 2023); 15% ↓ costs | Public-private contracts (Pharmastar + regional health authorities) |
| Community Pharmacy Consultation Service | UK (NHS) | Minor illness triage + medication reviews | 10% ↑ patient satisfaction; £50M annual savings (NHS England) | Publicly funded (NHS) |
| Apotheker in der Hausarztpraxis | Germany | Embedded in GP practices for chronic care | 12% ↑ adherence for hypertension (BAV) | Insurance reimbursement |
| Farmàcies de Servei | Catalonia, Spain | Vaccinations + health screenings | 30% ↑ flu vaccination rates (Generalitat de Catalunya) | Regional government grants |
Critical difference: While the UK and Germany focus on pharmacists working within GP practices or hospitals, Progetto Relazioni leverages Italy’s dense pharmacy network (one pharmacy per 1,500 people) to bring care to patients’ neighborhoods—a model that could be particularly effective in rural areas where GP access is limited.
Challenges: Can Italy Scale This Successfully?
Despite early successes, three hurdles threaten Progetto Relazioni’s expansion:
- Regulatory barriers: Italy’s Legge 475/1998 restricts pharmacists from diagnosing or prescribing. Pharmastar has secured temporary exemptions for Progetto Relazioni, but permanent changes require national legislation—a process that could take years. “We’re operating in a legal gray area,” admits Pharmastar CEO Marco Bianchi in a 2024 interview.
- Reimbursement models: Without clear funding mechanisms, regional health authorities may hesitate to adopt the program. Emilia-Romagna’s pilot was funded through a mix of Pharmastar investments and EU structural funds, but Lombardy’s rollout faces delays due to budget disputes.
- Pharmacist workforce constraints: Italy has 60,000 pharmacists, but only 15% are trained in clinical care. Pharmastar is partnering with universities to create 500 specialized roles annually, but critics argue this is insufficient to meet demand.
What’s next: The Italian Ministry of Health is reviewing Progetto Relazioni for inclusion in the 2025 national healthcare plan. If approved, the initiative could expand to 500 pharmacies nationwide by 2026, serving 2 million patients.
What This Means for Patients—and Other Countries
For Italians, Progetto Relazioni offers tangible benefits: shorter wait times, fewer medication errors, and more personalized care. But the broader implications extend beyond borders:
- For aging societies: Models like this could alleviate pressure on overburdened primary care systems in countries like Japan, Spain, and the U.S., where GP shortages are acute.
- For healthcare costs: The OECD estimates that integrated pharmacy services could save Europe €15 billion annually by reducing hospitalizations and improving adherence.
- For pharmacists’ professional evolution: Italy’s shift aligns with global trends—60% of European pharmacists now want expanded clinical roles, per a 2023 European Journal of Pharmacy survey.
Dr. Fischer notes: “This isn’t just about moving medications from shelves to consultations. It’s about redefining the role of pharmacists as active participants in preventive care—a shift that could transform healthcare delivery worldwide.”
Where to Find Official Updates
For the latest on Progetto Relazioni’s expansion and policy developments, consult these verified sources:
- Italian Ministry of Health Annual Report (2023)
- Pharmastar’s Official Program Page
- Italian Pharmacists Association (Federfarma) Updates
- OECD Analysis of Italian Healthcare Reforms
Reader Q&A: Key Questions Answered
1. Will Progetto Relazioni reduce my pharmacy bill?
Not directly. The initiative is funded through public-private partnerships and regional health budgets, not patient fees. However, by improving medication adherence and reducing hospitalizations, it may lower long-term healthcare costs for the system—and indirectly for insured patients.
2. Can pharmacists prescribe medications under this program?
No. Current Italian law prohibits pharmacists from prescribing. Progetto Relazioni pharmacists can only adjust dosages within pre-approved protocols (e.g., for insulin or inhalers) and refer patients to GPs for new prescriptions.
3. How do I access Progetto Relazioni services?
Services are available at participating Pharmastar locations (check here for a map). Patients can self-refer or be directed by their GP. Priority is given to those with chronic conditions or complex medication regimens.
4. Is this model being tested in other countries?
Yes. Spain’s Catalonia region and the UK’s NHS are exploring similar pharmacist-led care models, though none have scaled as broadly as Italy’s initiative. Pharmastar has expressed interest in exporting the model to Portugal and Greece.
Next checkpoint: The Italian Ministry of Health will publish a final evaluation of Progetto Relazioni’s first two years in November 2024, which will determine whether the program receives permanent legislative backing. Watch for updates on the Ministry’s website.
Have you experienced Progetto Relazioni’s services? Share your feedback in the comments—or tag us on X to tell us how healthcare access has changed in your community.